Results 1 to 10 of about 139,045 (309)

Acute lymphoblastic leukemia [PDF]

open access: yesPediatric Blood & Cancer, 2021
AbstractThe survival of patients with acute lymphoblastic leukemia (ALL) has improved significantly with the use of intensive multimodality treatment regimens including chemotherapy, high‐dose chemotherapy and stem cell rescue, and radiation therapy when indicated.
John Han‐Chih Chang   +4 more
  +6 more sources

Asciminib for relapsed or refractory Philadelphia chromosome–positive acute lymphoblastic leukemia [PDF]

open access: yesBlood Advances
Mathilde Chanut   +28 more
doaj   +2 more sources

Acute Lymphoblastic Leukemia [PDF]

open access: yesJournal of the National Comprehensive Cancer Network, 2012
The inaugural NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for acute lymphoblastic leukemia (ALL) were developed as a result of meetings convened by a multi-disciplinary panel of experts in 2011. These NCCN Guidelines provide recommendations on the diagnostic evaluation and workup for ALL, risk assessment, risk-stratified treatment ...
Joseph C, Alvarnas   +26 more
openaire   +4 more sources

A case of therapy-related acute lymphoblastic leukemia following the treatment of acute myeloid leukemia

open access: yesLeukemia Research Reports, 2022
Therapy-related acute lymphoblastic leukemia represents a distinct entity associated with inferior survival compared with de novo acute lymphoblastic leukemia.
Sufana Shikdar   +2 more
doaj   +1 more source

Antileukemic Efficacy of Continuous vs Discontinuous Dexamethasone in Murine Models of Acute Lymphoblastic Leukemia. [PDF]

open access: yesPLoS ONE, 2015
Osteonecrosis is one of the most common, serious, toxicities resulting from the treatment of acute lymphoblastic leukemia. In recent years, pediatric acute lymphoblastic leukemia clinical trials have used discontinuous rather than continuous dosing of ...
Laura B Ramsey   +12 more
doaj   +1 more source

Adult Acute Lymphoblastic Leukemia [PDF]

open access: yesMayo Clinic Proceedings, 2005
Much progress has been made in understanding the biology of and therapy for acute lymphoblastic leukemia (ALL). This progress has translated into the recognition of several subgroups of ALL and the institution of risk-adapted therapies. New therapies are emerging based on the definition of specific cytogenetic-molecular abnormalities.
Shilpa, Paul   +2 more
openaire   +3 more sources

B-Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma [PDF]

open access: yesAmerican Journal of Clinical Pathology, 2015
This session of the 2013 Society of Hematopathology/European Association for Haematopathology Workshop was dedicated to B-acute lymphoblastic leukemia (B-ALL)/lymphoblastic lymphoma (LBL) with recurrent translocations and not otherwise specified.In this review, we summarize the cases discussed during the workshop, review the pertinent and most recent ...
Sanam, Loghavi   +2 more
openaire   +2 more sources

Relapsed Acute Lymphoblastic Leukemia

open access: yesIndian Journal of Pediatrics, 2023
AbstractOutcomes for children with acute lymphoblastic leukemia (ALL) have improved worldwide to >85%. For those who relapse, outcomes have remained static at ~50% making relapsed acute lymphoblastic leukemia one of the leading causes of death in childhood cancers.
Sidhu, Jasmeet   +3 more
openaire   +3 more sources

CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia

open access: yesHaematologica, 2019
The potential of CD123-targeted therapies in acute lymphoblastic leukemia/lymphoma remains largely unexplored. We examined CD123 expression levels in a large cohort of patients with acute lymphoblastic leukemia/lymphoma and assessed the in vitro impact ...
Evgeniya Angelova   +14 more
doaj   +1 more source

Home - About - Disclaimer - Privacy